All In Biotech

Drug Trial Radar · NCT01151137

Permanent Atrial fibriLLAtion Outcome Study Using Dronedarone on Top of Standard Therapy

A Randomized, Double Blind, Placebo Controlled, Parallel Group Trial for Assessing the Clinical Benefit of Dronedarone 400mg BID on Top of Standard Therapy in Patients With Permanent Atrial Fibrillation and Additional Risk Factors

Last checked: Nov 19, 2026Latest source record: Oct 26, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 3,236 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

3,236

Actual

Start

Jul 2010

Primary completion

Sep 2011

Study completion Sep 2011

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Jun 25, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Objective: * Demonstrate the efficacy of Dronedarone in preventing major cardiovascular events (stroke, systemic arterial embolism, myocardial infarction or cardiovascular death) or unplanned cardiovascular hospitalization or death from any cause in patients with permanent Atrial Fibrillation \[AF\] and additional risk factors Secondary Objective: * Demonstrate the efficacy of Dronedarone in preventing cardiovascular death This was an event-driven study where a common study end date \[CSED\] was to be determined by Steering Committee based on the number of events (stroke, systemic arterial embolism, myocardial infarction or cardiovascular death).

Conditions

  • Atrial Fibrillation

Interventions

  • DronedaroneDrug

    Film-coated tablet Oral administration under fed conditions (during breakfast and dinner)

  • Placebo (for Dronedarone)Drug

    film-coated tablet strictly identical in appearance Oral administration under fed conditions (during breakfast and dinner)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overview of the Two Co-primary OutcomesTime frame: From randomization up to the CSED which occurred at study termination (maximum follow-up of 1 year)
  2. Time to First Co-primary Outcome (Cumulative Incidence Function)Time frame: From randomization up to the CSED which occurred at study termination (maximum follow-up of 1 year)
  3. Time to Second Co-primary Outcome (Cumulative Incidence Function)Time frame: From randomization up to the CSED which occurred at study termination (maximum follow-up of 1 year)

Locations

37 sites in 37 countries. Site status is shown where the registry gives one.

  • Sanofi-Aventis Administrative Office

    Bridgewater, New Jersey

  • Sanofi-Aventis Administrative Office

    Buenos Aires, Argentina

  • Sanofi-Aventis Administrative Office

    Macquarie Park, Australia

  • Sanofi-Aventis Administrative Office

    Vienna, Austria

  • Sanofi-Aventis Administrative Office

    Diegem, Belgium

  • Sanofi-Aventis Administrative Office

    São Paulo, Brazil

  • Sanofi-Aventis Administrative Office

    Sofia, Bulgaria

  • Sanofi-Aventis Administrative Office

    Laval, Canada

  • Sanofi-Aventis Administrative Office

    Providencia Santiago, Chile

  • Sanofi-Aventis Administrative Office

    Prague, Czechia

  • Sanofi-Aventis Administrative Office

    Hørsholm, Denmark

  • Sanofi-Aventis Administrative Office

    Helsinki, Finland

  • Sanofi-Aventis Administrative Office

    Paris, France

  • Sanofi-Aventis Administrative Office

    Frankfurt, Germany

  • Sanofi-Aventis Administrative Office

    Kallithea, Greece

  • Sanofi-Aventis Administrative Office

    Hong Kong, Hong Kong

  • Sanofi-Aventis Administrative Office

    Budapest, Hungary

  • Sanofi-Aventis Administrative Office

    Netanya, Israel

  • Sanofi-Aventis Administrative Office

    Milan, Italy

  • Sanofi-Aventis Administrative Office

    Kuala Lumpur, Malaysia

  • Sanofi-Aventis Administrative Office

    Col. Coyoacan, Mexico

  • Sanofi-Aventis Administrative Office

    Gouda, Netherlands

  • Sanofi-Aventis Administrative Office

    Auckland, New Zealand

  • Sanofi-Aventis Administrative Office

    Lysaker, Norway

  • Sanofi-Aventis Administrative Office

    Warsaw, Poland

  • Sanofi-Aventis Administrative Office

    Bucharest, Romania

  • Sanofi-Aventis Administrative Office

    Moscow, Russia

  • Sanofi-Aventis Administrative Office

    Singapore, Singapore

  • Sanofi-Aventis Administrative Office

    Bratislava, Slovakia

  • Sanofi-Aventis Administrative Office

    Gauteng, South Africa

  • Sanofi-Aventis Administrative Office

    Seoul, South Korea

  • Sanofi-Aventis Administrative Office

    Barcelona, Spain

  • Sanofi-Aventis Administrative Office

    Bromma, Sweden

  • Sanofi-Aventis Administrative Office

    Geneva, Switzerland

  • Sanofi-Aventis Administrative Office

    Taipei, Taiwan

  • Sanofi-Aventis Administrative Office

    Kiev, Ukraine

  • Sanofi-Aventis Administrative Office

    Guildford Surrey, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.